| Company Name: |
BOC Sciences |
| Tel: |
16314854226 |
| Email: |
inquiry@bocsci.com |
|
| | 8-BROMOADENOSINE-3',5'-CYCLIC MONOPHOSPHOROTHIOATE, RP-ISOMER SODIUM SALT Basic information |
| Product Name: | 8-BROMOADENOSINE-3',5'-CYCLIC MONOPHOSPHOROTHIOATE, RP-ISOMER SODIUM SALT | | Synonyms: | 8-BROMOADENOSINE-3',5'-CYCLIC * MONOPHOSPHOROTHIOAT;8-Bromoadenosine-3'',5''-cyclic monophosphothioate Rp isomer;RP-8-BR-CAMPS;RP-8-BR-CAMPS, NA;RP-8-BR-CAMPS SODIUM SALT;8-bromoadenosine-3’,5’-cyclicmonophosphorothioate,rp-isomer(rp-8-br-camps),sodiumsalt;8-BROMOADENOSINE-3',5'-CYCLIC MONOPHOSPHOROTHIOATE, RP-ISOMER SODIUM SALT;8-BROMOADENOSINE-3',5'-CYCLIC MONOPHOSPHOROTHIOATE SODIUM SALT, RPISOMER | | CAS: | 129735-00-8 | | MF: | C10H11BrN5O5PS | | MW: | 424.17 | | EINECS: | | | Product Categories: | | | Mol File: | 129735-00-8.mol |  |
| | 8-BROMOADENOSINE-3',5'-CYCLIC MONOPHOSPHOROTHIOATE, RP-ISOMER SODIUM SALT Chemical Properties |
| Boiling point | 690.3±65.0 °C(Predicted) | | density | 2.70±0.1 g/cm3(Predicted) | | storage temp. | −20°C | | solubility | water: 40 mg/mL | | form | solid | | pka | -0.60±0.60(Predicted) | | Water Solubility | water: 40mg/mL |
| Safety Statements | 22-24/25 | | WGK Germany | 3 | | Storage Class | 11 - Combustible Solids |
| | 8-BROMOADENOSINE-3',5'-CYCLIC MONOPHOSPHOROTHIOATE, RP-ISOMER SODIUM SALT Usage And Synthesis |
| Uses | Rp-8-Br-cAMPS is an analog of cAMP and an inhibitor of PKA. Rp-8-Br-cAMPS occupies cAMP binding sites on PKA type I regulatory subunits, thereby preventing PKA dissociation and activation. Rp-8-Br-cAMPS can be used in the study of tumors and retrovirus-induced immune deficiency. Rp-8-Br-cAMPS also inhibits insulin secretion[1][2][3]. | | Biological Activity | Cell permeable: yes', 'Primary Target
PKA 1', 'Product does not compete with ATP.', 'Reversible: yes | | in vivo | Rp-8-Br-cAMPS (1 mg; intraperitoneal injection; 10 days) improves immune function in a mouse retrovirus infection model[3]. | Animal Model: | Murine leukemia retrovirus RadLV-Rs treated male C57BL/6 mice[3] | | Dosage: | 1 mg | | Administration: | Intraperitoneal injection (i.p.); 10 days | | Result: | Had no significant effect on the extent of lymphadenopathy and splenomegaly which is typical of RadLV-Rs retroviral infection.
Strongly increased responses to the anti-CD3 mAb.
Improved T cell responses.
|
| | References | [1] Raskovalova T, et al. Adenosine-mediated inhibition of cytotoxic activity and cytokine production by IL-2/NKp46-activated NK cells: involvement of protein kinase A isozyme I (PKA I). Immunol Res. 2006;36(1-3):91-9. DOI:10.1385/IR:36:1:91
[2] Yang S, et al. Enhanced cAMP protein kinase A signaling determines improved insulin secretion in a clonal insulin-producing beta-cell line (INS-1 832/13). Mol Endocrinol. 2004 Sep;18(9):2312-20. DOI:10.1210/me.2004-0148
[3] Nayjib B, et al. In vivo administration of a PKA type I inhibitor (Rp-8-Br-cAMPS) restores T-cell responses in retrovirus-infected mice[J]. The Open Immunology Journal, 2008, 1(1). |
| | 8-BROMOADENOSINE-3',5'-CYCLIC MONOPHOSPHOROTHIOATE, RP-ISOMER SODIUM SALT Preparation Products And Raw materials |
|